CU20190013A7 - Composiciones de vacunas multivalentes - Google Patents

Composiciones de vacunas multivalentes

Info

Publication number
CU20190013A7
CU20190013A7 CU2019000013A CU20190013A CU20190013A7 CU 20190013 A7 CU20190013 A7 CU 20190013A7 CU 2019000013 A CU2019000013 A CU 2019000013A CU 20190013 A CU20190013 A CU 20190013A CU 20190013 A7 CU20190013 A7 CU 20190013A7
Authority
CU
Cuba
Prior art keywords
ipv
rotavirus
antigens
compositions
multivalent
Prior art date
Application number
CU2019000013A
Other languages
English (en)
Other versions
CU24682B1 (es
Inventor
Rajeev Mhalasakant Dhere
Roger Glass
Baoming Jiang
Ravindra Bapurao Kadam
Abhijeet Sanjeev Kamble
Sambhaji Shankar Pisal
Rajendra Narayan Sabale
Jagdish Kamalaji Zade
Original Assignee
Serum Institute Of India Pvt Ltd
The Centers For Disease Control And Prevention Cdc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd, The Centers For Disease Control And Prevention Cdc filed Critical Serum Institute Of India Pvt Ltd
Publication of CU20190013A7 publication Critical patent/CU20190013A7/es
Publication of CU24682B1 publication Critical patent/CU24682B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>La presente invención se refiere a composiciones de vacunas multivalentes que comprenden una mezcla de antígenos para Ia prevención y profilaxis de infecciones causadas por rotavirus, poliovirus, Haemophilus influenzae, Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis y Hepatitis B virus, así como el proceso de fabricación de las mismas. La invención, en particular, se refiere a una vacuna de combinación multivalente estable que comprende antígenos de Salk IPV o Sabin IPV (IPV) significativamente reducidos y antígeno (s) inyectable de Rotavirus, inactivado por calor, obtenido de cepas de Rotavirus (CDC -9).</p>
CU2019000013A 2016-08-26 2017-08-24 Una composición de vacuna multivalente compuesta por una mezcla de antígenos provenientes de virus de polio y rotavirus inactivados CU24682B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621029037 2016-08-26
PCT/IB2017/055100 WO2018037365A1 (en) 2016-08-26 2017-08-24 Multivalent vaccine composition

Publications (2)

Publication Number Publication Date
CU20190013A7 true CU20190013A7 (es) 2019-10-04
CU24682B1 CU24682B1 (es) 2023-10-06

Family

ID=60083359

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000013A CU24682B1 (es) 2016-08-26 2017-08-24 Una composición de vacuna multivalente compuesta por una mezcla de antígenos provenientes de virus de polio y rotavirus inactivados

Country Status (17)

Country Link
US (1) US11235054B2 (es)
EP (1) EP3503917A1 (es)
JP (3) JP7384667B2 (es)
KR (1) KR102607295B1 (es)
CN (1) CN110691611A (es)
AU (1) AU2017316768B2 (es)
BR (1) BR112019003419A2 (es)
CA (1) CA3032901A1 (es)
CU (1) CU24682B1 (es)
EA (1) EA201900117A1 (es)
IL (1) IL264605B2 (es)
MX (1) MX2019001780A (es)
MY (1) MY191163A (es)
PE (1) PE20200004A1 (es)
PH (1) PH12019500404A1 (es)
SG (1) SG11201900365WA (es)
WO (1) WO2018037365A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019003419A2 (pt) * 2016-08-26 2019-05-21 Serum Institute Of India Private Limited composição de vacina multivalente
US11793873B2 (en) 2017-05-10 2023-10-24 University Of Massachusetts Bivalent dengue/hepatitis B vaccines
JOP20190242A1 (ar) * 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2605179A1 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics, Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
AU2007293672B2 (en) * 2006-09-07 2013-06-27 Glaxosmithkline Biologicals S.A. Vaccine
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
EP3427750A1 (en) * 2009-05-12 2019-01-16 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services New human rotavirus strains and vaccines
CN103442730B (zh) * 2011-01-05 2016-08-17 巴拉特生物技术国际有限公司 组合七价疫苗
ES2681698T3 (es) * 2011-03-02 2018-09-14 Glaxosmithkline Biologicals Sa Vacunas de combinación con menores dosis de antígeno y/o adyuvante
KR102219638B1 (ko) 2014-10-07 2021-02-23 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 엔테로바이러스 불활화 및 보강제 흡착 방법과 이로부터 수득되는 저용량 백신 조성물
BR112019003419A2 (pt) * 2016-08-26 2019-05-21 Serum Institute Of India Private Limited composição de vacina multivalente

Also Published As

Publication number Publication date
SG11201900365WA (en) 2019-02-27
KR20190142311A (ko) 2019-12-26
US20190175722A1 (en) 2019-06-13
WO2018037365A1 (en) 2018-03-01
IL264605A (en) 2019-02-28
EP3503917A1 (en) 2019-07-03
MX2019001780A (es) 2020-01-13
EA201900117A1 (ru) 2019-09-30
MY191163A (en) 2022-06-03
AU2017316768B2 (en) 2024-04-11
IL264605B (en) 2022-12-01
CN110691611A (zh) 2020-01-14
JP2024009899A (ja) 2024-01-23
US11235054B2 (en) 2022-02-01
BR112019003419A2 (pt) 2019-05-21
JP7384667B2 (ja) 2023-11-21
CA3032901A1 (en) 2018-03-01
JP2019526635A (ja) 2019-09-19
JP2021181445A (ja) 2021-11-25
KR102607295B1 (ko) 2023-11-29
WO2018037365A8 (en) 2018-09-20
CU24682B1 (es) 2023-10-06
AU2017316768A1 (en) 2019-04-11
PE20200004A1 (es) 2020-01-06
IL264605B2 (en) 2023-04-01
PH12019500404A1 (en) 2020-01-20

Similar Documents

Publication Publication Date Title
CU20190013A7 (es) Composiciones de vacunas multivalentes
UY37811A (es) Una composición inmunogénica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparación de la misma
WO2012093406A3 (en) A combination heptavalent vaccine
PE20160686A1 (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b
BR112018002406A2 (pt) anticorpos que neutralizam potentemente o vírus da hepatite b e usos dos mesmos
CO6430434A2 (es) Nuevas composiciones de vacunas con pertussis acelular y método de fabricación de las mismas
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
EP4233898A3 (en) Influenza mrna vaccines
MX2023000211A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
EA202091513A1 (ru) Вакцины против вируса гепатита b (hbv) и их применение
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
CO6430435A2 (es) Nuevas vacunas combinadas con células completas de pertussis y método de fabricación de las mismas
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
AR090918A1 (es) COMPOSICION QUE COMPRENDE UN EPITOPO DE a-SINUCLEINA ACOPLADO O FUSIONADO A UNA TOXINA MUTADA DE LA DIFTERIA NO TOXICA
BR112021012496A2 (pt) Enterovírus adaptado bem como seu método e processo de adaptação, sequências de nucleotídeo e aminoácido, método para inativar enterovírus e composição imunogênica
MY163742A (en) Epitope and its use of hepatitis b virus surface antigen
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
PE20211648A1 (es) Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma
AR101256A1 (es) Composición vacunal que comprende ipv y ciclodextrinas
PH12015502207A1 (en) Stabilised fmdv capsids
AR117191A1 (es) Composiciones inmunogénicas
CO2020011984A2 (es) Cepa del virus de la fiebre amarilla viva atenuada adaptada para el crecimiento en células vero y composición de vacuna que la comprende
MY188494A (en) High-growth enterovirus 71 strains and vaccines
AR109291A1 (es) Clon de adnc del virus del síndrome reproductivo y respiratorio porcino y usos del mismo